Disc Medicine to Present Phase 2 Hematology Data at SOHO 2026
Question
Disc Medicine to Present Phase 2 Hematology Data at SOHO 2026
Direct answer
Disc Medicine confirmed it will deliver scientific presentations at the Society of Hematologic Oncology 2026 Annual Meeting in Houston. The readouts include Phase 2 RESTORE-PV results evaluating DISC-3405 in polycythemia vera and Phase 2 RALLY-MF data assessing DISC-0974 in myelofibrosis-associated anemia. The reported findings will provide clinical validation on therapeutic efficacy and safety parameters across Disc Medicine's core erythroid and iron biology drug pipeline.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-01
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Disc Medicine to Present Phase 2 Hematology Data at SOHO 2026”, revision 1, evidence through 2026-09-01. https://marketontology.com/market-events/2026-09-01/disc-medicine-to-present-phase-2-hematology-data-at-soho-2026-92ef1b
How this development reaches the affected companies
| Asset | Exposure and channel | Direction | Evidence |
|---|---|---|---|
| IRON | clinical pipeline trial efficacy readout derisking | Up1-5d | Disc Medicine presenting Phase 2 data for DISC-3405 and DISC-0974 at SOHO 2026 |
Does this development affect your holdings?
Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.